Drug Delivery in Cancer Treatment II

1. Front Matter

   Pages i-vii

   PDF

2. Introduction

   • L. Domellöf

   Pages 1-2

3. Analgesic Drugs in Palliative Care

   • V. Ventafridda, A. Caraceni, A. Sbanotto, E. Spoldi, F. De Conno

   Pages 3-13

4. Pharmacokinetic Aspects of Drug-Drug and Drug-Plastic Interactions with Anticancer Drugs

   • Lennart K. Paalzow

   Pages 15-29

5. Immunotherapy and Interactions of Cytokines in the Host

   • K. G. Lundholm

   Pages 31-42

6. The Rationale of Intraarterial Chemotherapy of Liver Cancer

   • P. Schlag, P. Hohenberger

   Pages 43-53

7. Chemoembolisation in Regional Chemotherapy

   • H. P. J. M. Noteborn, J. G. McVie

   Pages 55-78

8. Optimised Treatment Modalities for Hypoxic Tumour Cells

   • P. Workman

   Pages 79-102

9. Drug Delivery to Cancer Patients in Home Care: Experience with Intraarterial and Intravenous Chemotherapy

   • P. Schlag, A. Schwarz, S. Frohmüller

   Pages 103-107

The European School of Oncology came into existence to respond to a need for information, education and training in the field of the diagnosis and treatment of cancer. There are two main reasons why such an initiative was considered necessary. Firstly, the teaching of oncology requires a rigorously multidiscipli­ nary approach which is difficult for the Universities to put into practice since their system is mainly disciplinary orientated. Secondly, the rate of technological development that impinges on the diagnosis and treatment of cancer has been so rapid that it is not an easy task for medical faculties to adapt their curricula flexibly. With its residential courses for organ pathologies and the seminars on new techniques (laser, monoclonal antibodies, imaging techniques etc.) or on the principal therapeutic controversies (conservative or mutilating surgery, primary or adjuvant chemotherapy, radiotherapy alone or integrated), it is the ambition of the European School of Oncology to fill a cultural and scientific gap and, thereby, create a bridge between the University and Industry and between these two and daily medical practice. One of the more recent initiatives of ESO has been the institution of permanent study groups, also called task forces, where a limited number of leading experts are invited to meet once a year with the aim of defining the state of the art and possibly reaching a consensus on future developments in specific fields of on­ cology.

• Behandlungsstrategien
• Immuntherapie
• Schmerzbehandlung
• imaging
• imaging techniques
• intraarterielle Chemotherapie
• regionale Chemotherapie
• surgery

• Department of Surgery, Regional Hospital, Örebro, Sweden

  Lennart Domellöf

Policies and ethics